Your browser is no longer supported. Please, upgrade your browser.
NEO NeoGenomics, Inc. monthly Stock Chart
NeoGenomics, Inc.
Index- P/E1250.31 EPS (ttm)0.03 Insider Own2.90% Shs Outstand107.89M Perf Week4.36%
Market Cap4.43B Forward P/E99.28 EPS next Y0.40 Insider Trans-13.74% Shs Float105.27M Perf Month10.80%
Income3.50M PEG111.64 EPS next Q0.05 Inst Own87.00% Short Float5.07% Perf Quarter44.86%
Sales419.30M P/S10.57 EPS this Y16.20% Inst Trans1.23% Short Ratio5.43 Perf Half Y27.42%
Book/sh6.06 P/B6.60 EPS next Y660.38% ROA- Target Price40.93 Perf Year53.88%
Cash/sh2.67 P/C15.01 EPS next 5Y11.20% ROE- 52W Range18.52 - 40.68 Perf YTD36.79%
Dividend- P/FCF- EPS past 5Y30.80% ROI2.70% 52W High-1.65% Beta0.82
Dividend %- Quick Ratio6.40 Sales past 5Y36.20% Gross Margin46.80% 52W Low116.04% ATR1.57
Employees1700 Current Ratio6.80 Sales Q/Q-14.50% Oper. Margin- RSI (14)71.28 Volatility3.90% 3.84%
OptionableYes Debt/Eq0.26 EPS Q/Q- Profit Margin- Rel Volume0.67 Prev Close40.32
ShortableYes LT Debt/Eq0.25 EarningsJul 28 BMO Payout- Avg Volume982.02K Price40.01
Recom1.50 SMA208.23% SMA5024.35% SMA20038.87% Volume659,694 Change-0.77%
Jul-29-20Reiterated Needham Buy $33 → $39
Jun-25-20Initiated BofA/Merrill Buy $34
Apr-21-20Resumed Stephens Overweight $33
Mar-02-20Resumed Craig Hallum Buy $38
Feb-28-20Upgrade First Analysis Sec Outperform → Strong Buy
Jan-23-20Downgrade First Analysis Sec Strong Buy → Outperform $29 → $35
Oct-30-19Reiterated Needham Buy $27 → $29
May-01-19Reiterated Needham Buy $22 → $24
Mar-29-19Reiterated Needham Buy $19 → $22
Jan-03-19Initiated Needham Buy $14
Oct-24-18Upgrade First Analysis Sec Outperform → Strong Buy $18
Aug-21-18Initiated Leerink Partners Outperform $18
May-02-18Downgrade First Analysis Sec Overweight → Equal-Weight $11
Sep-11-17Downgrade BTIG Research Buy → Neutral
Aug-24-17Initiated Gabelli & Co Buy $9
Dec-15-16Initiated Cantor Fitzgerald Overweight $11
Oct-04-16Initiated First Analysis Sec Overweight $11
Jul-27-16Reiterated The Benchmark Company Buy $10 → $12
Apr-28-16Reiterated The Benchmark Company Buy $8 → $9
Mar-11-16Initiated The Benchmark Company Buy $8
Aug-06-20 01:43PM  
Aug-05-20 11:11AM  
Jul-30-20 10:52AM  
Jul-28-20 01:30PM  
Jul-21-20 12:31PM  
Jul-20-20 07:00AM  
Jul-12-20 06:12AM  
Jul-04-20 08:18PM  
Jul-01-20 07:00AM  
Jun-29-20 07:00AM  
Jun-25-20 10:10AM  
Jun-18-20 12:27PM  
Jun-12-20 01:50AM  
Jun-10-20 06:44PM  
Jun-02-20 04:05PM  
Jun-01-20 04:05PM  
May-26-20 07:20AM  
May-19-20 12:00AM  
May-11-20 04:05PM  
May-09-20 11:47AM  
May-05-20 08:00AM  
Apr-30-20 12:07PM  
Apr-29-20 05:20PM  
Apr-28-20 04:00PM  
Apr-27-20 04:00PM  
Apr-09-20 07:00AM  
Apr-03-20 07:00AM  
Apr-01-20 07:00AM  
Mar-29-20 12:12PM  
Mar-27-20 07:58AM  
Mar-02-20 07:00AM  
Mar-01-20 09:10AM  
Feb-28-20 07:00AM  
Feb-27-20 09:55AM  
Feb-20-20 12:31PM  
Feb-06-20 07:00AM  
Feb-05-20 07:00AM  
Jan-30-20 11:30AM  
Jan-17-20 10:45AM  
Jan-14-20 07:55AM  
Jan-10-20 08:40AM  
Dec-12-19 07:10PM  
Nov-06-19 04:05PM  
Nov-05-19 06:01PM  
Nov-01-19 11:34AM  
Oct-29-19 08:55AM  
Oct-24-19 02:07PM  
Oct-23-19 11:06AM  
Oct-01-19 04:05PM  
Sep-25-19 04:05PM  
Sep-17-19 07:49AM  
Sep-09-19 07:12AM  
Sep-03-19 04:15PM  
Aug-12-19 08:38AM  
Aug-08-19 08:45AM  
Aug-05-19 04:20PM  
Aug-02-19 06:41AM  
Aug-01-19 05:34PM  
Jul-31-19 07:00AM  
Jul-30-19 06:23PM  
Jul-23-19 10:32AM  
Jul-12-19 03:13PM  
Jul-11-19 10:38AM  
Jul-09-19 07:00AM  
Jul-01-19 04:01PM  
Jun-27-19 04:01PM  
Jun-23-19 03:51PM  
May-30-19 04:05PM  
May-28-19 06:00AM  
May-23-19 04:30PM  
May-21-19 08:10PM  
May-20-19 04:12PM  
May-07-19 12:16PM  
May-03-19 09:15AM  
May-02-19 02:40PM  
Apr-30-19 02:03PM  
Apr-23-19 10:32AM  
Apr-03-19 04:35PM  
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, as well as laboratories in Switzerland and Singapore. It operates in two segments, Clinical Services and Pharma Services. The company's laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, academic centers, and other clinical laboratories. It offers cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; immunohistochemistry and digital imaging testing services to localize proteins in cells of a tissue section, as well as to allow clients to see and utilize scanned slides, and perform quantitative analysis for various stains; and molecular testing services, which focus on the analysis of DNA and RNA, and the structure and function of genes at the molecular level. The company also provides morphologic analysis which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. NeoGenomics, Inc. has a strategic collaboration with Inivata Limited for the commercialization of its InVisionFirst-Lung liquid biopsy test in the United States. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BALLIET JENNIFERVP and Chief Culture OfficerAug 03Option Exercise7.5213,00097,76037,980Aug 04 06:01 PM
Bonello WilliamPresident, InformaticsAug 03Option Exercise7.5722,000166,44234,060Aug 04 06:33 PM
Bonello WilliamPresident, InformaticsAug 03Sale38.6122,000849,42012,060Aug 04 06:33 PM
BALLIET JENNIFERVP and Chief Culture OfficerAug 03Sale39.2513,000510,25024,980Aug 04 06:01 PM
SHOVLIN ROBERT J.President, Clinical ServicesJul 30Option Exercise9.9483,391829,126229,626Aug 03 07:26 PM
SHOVLIN ROBERT J.President, Clinical ServicesJul 30Sale38.1781,3563,105,359148,270Aug 03 07:26 PM
CROWTHER BRUCE KDirectorMay 01Option Exercise4.7810,00047,80046,185May 04 05:34 PM
JONES STEVEN CDirectorMar 13Option Exercise4.78125,000597,5001,500,000Mar 16 06:45 PM
SHOVLIN ROBERT J.President, Clinical ServicesMar 04Option Exercise8.0396,167772,221249,733Mar 05 08:14 PM
SHOVLIN ROBERT J.President, Clinical ServicesMar 04Sale30.8698,0933,027,150151,640Mar 05 08:14 PM
JONES STEVEN CDirectorMar 02Sale28.77297,3008,554,25230,476Mar 04 07:17 PM
JONES STEVEN CDirectorDec 30Option Exercise4.78100,000478,0001,625,000Jan 02 06:45 PM
McKenzie Kathryn BChief Accounting OfficerDec 10Option Exercise8.038,00064,24010,273Dec 12 07:28 PM
McKenzie Kathryn BChief Accounting OfficerDec 10Sale26.378,000210,9602,273Dec 12 07:28 PM
JONES STEVEN CDirectorNov 21Sale24.2723,162562,1421,525,000Nov 22 05:35 PM
JONES STEVEN CDirectorNov 20Sale24.35128,0683,118,4561,548,162Nov 22 05:35 PM
VAN OORT DOUGLAS MChairman and CEONov 19Sale24.08187,5004,515,0000Nov 21 05:32 PM
BALLIET JENNIFERVP and Chief Culture OfficerNov 15Option Exercise7.536,83351,46929,695Nov 18 12:30 PM
BALLIET JENNIFERVP and Chief Culture OfficerNov 15Sale23.456,833160,23422,862Nov 18 12:30 PM
CARDOZA GEORGEPresident, Pharma ServicesNov 12Option Exercise7.1544,444317,775345,275Nov 14 05:11 PM
CARDOZA GEORGEPresident, Pharma ServicesNov 12Sale23.1519,444450,129325,831Nov 14 05:11 PM
VAN OORT DOUGLAS MChairman and CEONov 08Option Exercise7.15472,5273,378,5682,483,026Nov 13 05:43 PM
CARDOZA GEORGEPresident, Pharma ServicesNov 07Sale22.804,00091,200300,831Nov 08 04:47 PM
CARDOZA GEORGEPresident, Pharma ServicesNov 06Option Exercise7.1555,556397,225356,387Nov 08 04:47 PM
CARDOZA GEORGEPresident, Pharma ServicesNov 06Sale22.8251,5561,176,508304,831Nov 08 04:47 PM
SHOVLIN ROBERT J.President, Clinical ServicesNov 01Sale22.7435,801814,115145,640Nov 04 06:07 PM
SHOVLIN ROBERT J.President, Clinical ServicesOct 31Option Exercise8.0396,166772,213251,914Nov 04 06:07 PM
Johnson Kevin CDirectorOct 31Option Exercise7.7524,683191,24152,968Nov 04 06:15 PM
SHOVLIN ROBERT J.President, Clinical ServicesOct 31Sale23.1170,4731,628,631181,441Nov 04 06:07 PM
JONES STEVEN CDirectorSep 10Sale21.471,20025,76446,457Sep 10 08:32 PM
HANNAH ALISON L.DirectorSep 09Option Exercise8.4111,66698,11176,098Sep 11 08:00 PM
JONES STEVEN CDirectorSep 09Sale25.003751,676,230Sep 10 08:32 PM
JONES STEVEN CDirectorSep 06Sale25.001,69142,2751,676,233Sep 10 08:32 PM
JONES STEVEN CDirectorAug 30Sale25.001,20030,0001,677,924Aug 30 05:10 PM
Bonello WilliamChief Strategy OfficerAug 28Option Exercise7.5217,000127,84023,735Aug 30 05:15 PM
Bonello WilliamChief Strategy OfficerAug 28Sale24.8317,000422,1106,735Aug 30 05:15 PM
JONES STEVEN CDirectorAug 28Sale25.0239,537989,2161,679,124Aug 30 05:10 PM
JONES STEVEN CDirectorAug 27Sale24.9530,280755,4861,718,661Aug 27 05:40 PM
JONES STEVEN CDirectorAug 26Sale24.87143,6033,571,4071,748,941Aug 27 05:40 PM
Johnson Kevin CDirectorAug 26Sale24.7411,800291,93228,285Aug 27 05:41 PM
HIPP RAYMOND RDirectorAug 26Sale24.7915,424382,361134,102Aug 27 05:44 PM
HIPP RAYMOND RDirectorAug 23Option Exercise9.269,12784,527150,126Aug 27 05:44 PM
HIPP RAYMOND RDirectorAug 23Sale25.0260015,012149,526Aug 27 05:44 PM
Johnson Kevin CDirectorAug 23Sale25.6041,2001,054,72040,085Aug 27 05:41 PM
JONES STEVEN CDirectorAug 23Sale25.727,456191,7681,892,544Aug 27 05:40 PM